PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

COVID’s US toll projected to drop sharply by the end of July

Show Me

Canada authorizes Pfizer vaccine for age 12 and older

Show Me

Honeywell Fined $13 Million For Exporting Sensitive Information to Countries Including China

Show Me

Peloton treadmills recalled after a child dies; CEO apologizes for ‘mistake’ in initial response

Show Me

British woman murdered in Pakistan after refusing marriage proposals: report

Show Me

Left-Wing Media Watchdog Defends Jennifer Granholm’s Wealth After Helping Her Become a Millionaire

Show Me

In Virtual Town Hall, U.S. Army Sought to Convert — and Coerce — Vaccine Skeptics

Show Me

Coca-Cola Chief Lawyer Who Demanded Race Quotas for Attorneys Resigns, Gets Rehired for $666,666 per Month

Show Me

This Is Only One Of Many Reasons Americans Distrust Doctor Fauci & The CDC | Vaccine Side Effects Americans Tell One Another | Video: 2 Minutes 26 Seconds

Show Me

Nashville Police Officer Shot After ‘Setup’ 911 Call Lured Responders Into Ambush

Show Me

Trump/Owens 2024: Candace Owens wants on the ticket, asks Trump ‘Can I be your vice president?’

Show Me

G-7 Signals Deep Concern Over Alleged China Human-Rights Abuses

Show Me

Exposed: Government-Sponsored Experiments on Aborted Human Fetuses at the University of Pittsburgh – FETUS TRAFFICKING

Show Me

An Alarming Number of Young Men and Boys in Myanmar Have Been ‘Disappeared’ by the Military

Show Me

May 5, 2021 | Nightly News Rebroadcast | Video: 54 Minutes 35 Seconds

Show Me

‘From the Desk of’: Trump unveils online platform, upstages impending ruling on Facebook access

Show Me

Republicans: Break Up Big Tech After Facebook Board Upholds Trump Ban

Show Me

Trump Endorses Elise Stefanik to Replace Liz Cheney in House GOP Leadership

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded May 5, 2021 | Video: 48 Minutes 38 Seconds

Show Me

UNEARTHED: 1619 Project Founder Praised Cuba’s ‘Socialist’ Accomplishments, Counts Education As ‘Cornerstone Of Revolution.’

Show Me

Mexican agencies won’t help US topple drug cartels, senior DEA official says

Show Me

Fauci Admits CDC Guidelines For Kids To Wear Masks Outdoors In 90-Degree Weather May Not Be ‘Sensible’

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded May 5, 2021 | Video: 48 Minutes 40 Seconds

Show Me

Facebook Declares Donald Trump will Stay Banned from the Platform … But Only for Six Months?

Show Me

Facebook Oversight Board Upholds Suspension of Donald Trump’s Account

Show Me

Trump Allies Launch Nonprofit Focused on Election Fraud

Show Me

Bannon’s War Room | Evening Edition | Recorded May 5, 2021 | Video: 48 Minutes 59 Seconds

Show Me

Pfizer anticipates seeking emergency use authorization in September for kids 2 to 11 to take vaccine

Show Me

CA Officials Request Big Tech Censorship

Show Me

Antifa Goon Jumps on Elderly Man’s Car, Quickly Discovers How Gravity and Horsepower Work

Show Me

American Medical Association CEO Calls Laws Banning Kids Trans Surgeries ‘Dangerous Governmental Intrusion’

Show Me

Americans Are Finding It Increasingly Difficult To Take The Media Seriously | AP Uses Poll To Accuse Americans Of Their Own Failures

Show Me

Record-low U.S. birth rate fell another 4% in 2020, CDC says

Show Me

Vaccine info site: CENSORED

Show Me

Exclusive— Andrew Wilkow: ‘Woke Left’ Makes ‘Pearl-Clutching Conservatives from the 80s Look Like Cardi B’

Show Me

Freddy Got Fingered – The Official Trailer | Video: 2 Minutes 19 Seconds

Show Me

20 years ago ‘Freddy Got Fingered’ Disgusted the Nation — Has Its Time Arrived?

Show Me

The Worst of Both Worlds — Genetically Engineered Goats to Produce New Vaccine

Show Me

House GOP Leader Kevin McCarthy Says Liz Cheney Leadership Ouster Likely Before the End of The Month – Perhaps Tucker Carlson Attacks on McCarthy Are Connected

Show Me

Bill Gates hires Warren Buffett’s right-hand man as his lawyer in split from wife Melinda

Show Me